Literature DB >> 12904144

Anticoagulant-related skin reactions.

I Jörg1, T Fenyvesi, J Harenberg.   

Abstract

Cutaneous reactions have been reported during anticoagulant therapy with coumarin derivatives, unfractionated and low molecular weight heparins, heparinoids, danaparoid and hirudins. Anticoagulant-induced skin reactions vary from local allergic manifestations to skin necrosis. In patients with allergic reactions, diagnosis and crossreactions between anticoagulants can be confirmed by intracutaneous testing. Coumarin- and heparin-induced skin necrosis are rare, but are important side effects due to their high morbidity and occasional mortality. Cutaneous tests are contraindicated in these patients. In the future, anticoagulant strategies may include direct synthetic thrombin inhibitors (argatroban and melagatran/ximelagatran) and the Factor Xa inhibitor, pentasaccharide (fondaparinux).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12904144     DOI: 10.1517/14740338.1.3.287

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  5 in total

1.  [Role of vitamin K antagonists from a hepatologist's point of view].

Authors:  G Kneiseler; A Canbay; G Gerken
Journal:  Herz       Date:  2012-06       Impact factor: 1.443

2.  A rare case report of apixaban-induced lichenoid eruption.

Authors:  Tanvi Patil; Suzanne Hanna; Wayne Torre
Journal:  Ther Adv Drug Saf       Date:  2020-08-17

3.  A mysterious postoperative rash.

Authors:  Maria Chicco; George Filobbos; Nicholas Francis; Paul Ziprin
Journal:  BMJ Case Rep       Date:  2018-05-15

Review 4.  Drug-induced skin, nail and hair disorders.

Authors:  Laurence Valeyrie-Allanore; Bruno Sassolas; Jean-Claude Roujeau
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  The health care setting rather than medical speciality impacts on physicians adherence to guideline-conform anticoagulation in outpatients with non-valvular atrial fibrillation: a cross sectional survey.

Authors:  Bernhard Gerber; Georg Stussi; Thomas Rosemann; Oliver Senn
Journal:  BMC Cardiovasc Disord       Date:  2012-02-29       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.